Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Pediatr Dermatol ; 31(1): 118-22, 2014.
Article in English | MEDLINE | ID: mdl-24106998

ABSTRACT

Accurate and objective measurement of volume changes in infantile hemangiomas (IHs) is essential in routine clinical practice and clinical studies, particularly in the changing therapeutic landscape after the discovery of propranolol. Several bedside techniques for volume measurement have been described in the literature, but an objective method of measurement of this variable, dynamic vascular tumor is lacking. Three-dimensional (3D) phototechnology with data analysis is an up-and-coming technique in the objective measurement of facial volume changes. In this pilot study, the usability and clinical relevance of two methods of 3D stereophotogrammetry in the volume measurement of IH were explored.


Subject(s)
Hemangioma/diagnosis , Imaging, Three-Dimensional/methods , Photogrammetry/methods , Skin Neoplasms/diagnosis , Body Surface Area , Face/pathology , Female , Hemangioma/pathology , Humans , Infant , Male , Pilot Projects , Prospective Studies , Skin Neoplasms/pathology
2.
Ned Tijdschr Geneeskd ; 155(40): A3482, 2011.
Article in Dutch | MEDLINE | ID: mdl-21988755

ABSTRACT

Infantile haemangiomas (IH) are the most commonly occurring benign tumours of infancy, which may lead to considerable morbidity, such as amblyopia, ulceration and airway obstruction, depending on localization. Until recently, treatment was difficult: high-dose systemic glucocorticoids had limited effect and serious side effects. In 2008, the effectiveness of the beta-blocker propranolol for infantile haemangiomas was discovered; by now there is extensive worldwide experience. Data from the literature and from our own patient cohort (n = 132) confirm the remarkable efficacy of propranolol in complicated IH, without significant adverse effects. Propranolol is most effective in the proliferation phase of IH in children under 6 months of age. Timely referral of patients with potentially function-threatening or life-changing IH to a specialised multidisciplinary centre is therefore essential. Pending controlled studies, propranolol appears to have become the first choice treatment in complicated IH.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Hemangioma/drug therapy , Propranolol/therapeutic use , Adrenergic beta-Antagonists/adverse effects , Child , Child, Preschool , Disease Progression , Humans , Infant , Infant, Newborn , Propranolol/adverse effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...